Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

Audio By Carbonatix

SAN FRANCISCO--(BUSINESS WIRE)--May 20, 2025--

Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, and Mika Kakefuda Derynck, M.D., Executive Vice President, Therapeutic Area Head, Oncology, will participate in a virtual fireside chat at the TD Cowen 6 th Annual Oncology Innovation Summit on Tuesday, May 27 at 1:30 p.m. PT / 4:30 p.m. ET.

A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.

About Vir Biotechnology

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250520403573/en/

CONTACT: Media

Corporate Communications, Vir Biotechnology

[email protected]

Richard Lepke

Senior Director, Investor Relations

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: ONCOLOGY HEALTH INFECTIOUS DISEASES CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Vir Biotechnology, Inc.

Copyright Business Wire 2025.

PUB: 05/20/2025 04:05 PM/DISC: 05/20/2025 04:04 PM

http://www.businesswire.com/news/home/20250520403573/en